Allergic contact dermatitis is a common disease within the family of delayed-type hypersensitivity reactions. In more severe cases of allergic contact dermatitis, topical steroids may prove insufficient, and systemic therapeutic agents are often used. Even when systemic therapies such as cyclosporine lead to improvement, withdrawal of these agents is challenging and can lead to undesirable morbidities. Currently, there are no systemic treatments indicated for the treatment of widespread recalcitrant contact dermatitis. This review discusses the targets of in-use off-label systemic medications and potential therapeutics in the pipeline.
Get full access to this article
View all access options for this article.
References
1.
WeeJS, WhiteJM, McFaddenJP, et al.Patch testing in patients treated with systemic immunosuppression and cytokine inhibitors. Contact Dermatitis, 2010; 62(3):165–169.
AnvedenI, LindbergM, AndersenKE, et al.Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis, 2004; 50:298–303.
CronsteinBN, NaimeD, OstadE. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest, 1993; 92(6):2675–1682.
8.
TianH, CronsteinBN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis, 2007; 65:168–173.
9.
Jeffes EWIII, McCulloughJL, PittelkowMR, et al.Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol, 1995; 104:183–188.
10.
PatelA, BurnsE, BurkemperNM. Methotrexate use in allergic contact dermatitis: a retrospective study. Contact Dermatitis, 2018; 78:194–198.
11.
SharmaVK, BhatR, SethuramanG, et al.Treatment of Parthenium dermatitis with methotrexate. Contact Dermatitis, 2007; 57:118–119.
12.
ShojiY, FukumuraT, KudoM, et al.Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene. J Pharm Pharmacol, 1994; 46:643–646.
SharmaVK, ChakrabartiA, MahajanV. Azathioprine in the treatment of Parthenium dermatitis. Int J Dermatol, 1998; 37:299–302.
15.
VermaKK, BansalA, SethuramanG. Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol, 2006; 72:24–27.
16.
AgarwalUS, BesarwalRK. Topical clobetasol propionate 0.05% cream alone and in combination with azathioprine in patients with chronic hand eczema: an observer blinded randomized comparative trial. Indian J Dermatol Venereol Leprol, 2013; 79:101–103.
17.
VermaKK, MaheshR, SrivastavaP, et al.Azathioprine versus betamethasone for the treatment of Parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol, 2008; 74:453–457.
18.
OosterhavenJA, PolitiekK, SchuttelaarMA. Azathioprine treatment and drug survival in patients with chronic hand eczema—results from daily practice. Contact Dermatitis, 2017; 76:304–307.
19.
PearceVJ, MortimerPS. Hand dermatitis and lymphoedema. Br J Dermatol, 2009; 161:177–180.
20.
KaushalK, ManchandaY. Long-term safety and toxicity of azathioprine in patients with air-borne contact dermatitis. Indian J Dermatol Venereol Leprol, 2001; 67:75–77.
21.
PrussickL, PlotnikovaN, GottliebA. Mycophenolate mofetil in severe atopic dermatitis: a review. J Drugs Dermatol, 2016; 15:715–718.
22.
AmnuaikitT, SongkramC, PinsuwanS. Enhancement of mycophenolate mofetil permeation for topical use by eucalyptol and N-methyl-2-pyrrolidone. Scientifica (Cairo), 2016; 2016:9672718.
23.
NguyenRH, CruzPDJr. Hepatitis due to mycophenolate mofetil used to treat atopic dermatitis and allergic contact dermatitis. Dermatitis, 2014; 25:284–285.
24.
HowieSE, AldridgeRD, McVittieE, et al.Epidermal keratinocyte production of interferon-gamma immunoreactive protein and mRNA is an early event in allergic contact dermatitis. J Invest Dermatol, 1996; 106:1218–1223.
25.
GuarneriF, MinciulloPL, MannucciC, et al.IL-31 and IL-33 circulating levels in allergic contact dermatitis. Eur Ann Allergy Clin Immunol, 2015; 47:156–158.
26.
TaniguchiK, YoshizakiA, YanabaK, et al.Interleukin 33 is induced by tumor necrosis factor alpha and interferon gamma in keratinocytes and contributes to allergic contact dermatitis. J Investig Allergol Clin Immunol, 2013; 23:428–434.
27.
OgawaA, YoshizakiA, YanabaK, et al.The differential role of L-selectin and ICAM-1 in TH1-type and TH2-type contact hypersensitivity. J Invest Dermatol, 2010; 130:1558–1570.
28.
LarsenJM, BonefeldCM, PoulsenSS, et al.IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol, 2009; 123:486–492.
29.
van BeelenAJ, TeunissenMB, KapsenbergML, et al.Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol, 2007; 7:374–381.
30.
HopkinsJE, NaisbittDJ, KitteringhamNR, et al.Selective haptenation of cellular or extracellular protein by chemical allergens: association with cytokine polarization. Chem Res Toxicol, 2005; 18:375–381.
31.
RomagnaniS. The TH1/TH2 paradigm. Immunol Today, 1997; 18:263–266.
32.
BordignonV, PalamaraF, Cordiali-FeiP, et al.Nickel, palladium and rhodium induced IFN-gamma and IL-10 production as assessed by in vitro ELISpot-analysis in contact dermatitis patients. BMC Immunol, 2008; 9:19.
33.
ForsbeckM, HovmarkA, SkogE. Patch testing, tuberculin testing and sensitization with dinitrochlorobenzene and nitrosodimethylanilini of patients with atopic dermatitis. Acta Derm Venereol, 1976; 56:135–138.
RingJ, AlomarA, BieberT, et al.Guidelines for treatment of atopic eczema (atopic dermatitis). Part II. J Eur Acad Dermatol Venereol, 2012; 26:1176–1193.
37.
GoujonC, ViguierM, Staumont-SalléD, et al.Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. J Allergy Clin Immunol Pract, 2018; 6(2):562.e3–569.e3.
GranlundH, ErkkoP, ErikssonE, et al.Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol, 1996; 76:371–376.
40.
PolitiekK, van der SchaftJ, ChristoffersWA, et al.Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study. J Eur Acad Dermatol Venereol, 2016; 30:1405–1407.
41.
PrignanoF, BoncioliniV, BoncianiD, et al.Exacerbation of allergic contact dermatitis during immunosuppression with cyclosporine A. G Ital Dermatol Venereol, 2010; 145:543–546.
42.
KunduRV, SchemanAJ, GutmanovichA, et al.Contact dermatitis to white petrolatum. Skinmed, 2004; 3:295–296.
43.
ThaçiD, KimballA, FoleyP, et al.Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol, 2017; 31(3):498–506.
44.
AbroukM, FarahnikB, ZhuTH, et al.Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol, 2017; 77:177–180.
45.
NotaroER, SidburyR. Systemic agents for severe atopic dermatitis in children. Paediatr Drugs, 2015; 17:449–457.
46.
VolfEM, AuSC, DumontN, et al.A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol, 2012; 11:341–346.
47.
WestCE, FowlerJF. Clearance of erythroderma in a patient on apremilast and positive patch test reactions while on treatment. Dermatitis, 2016; 27:392.
DittmarD, SchuttelaarML. Immunology and genetics of tumour necrosis factor in allergic contact dermatitis. Contact Dermatitis, 2017; 76:257–271.
50.
CumberbatchM, KimberI. Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration. Immunology, 1992; 75:257–263.
51.
CumberbatchM, KimberI. Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology, 1995; 84:31–35.
52.
HajeerAH, HutchinsonIV. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech, 2000; 50:216–228.
53.
WestphalGA, SchnuchA, MoessnerR, et al.Cytokine gene polymorphisms in allergic contact dermatitis. Contact Dermatitis, 2003; 48:93–98.
54.
KaplanDH, IgyartoBZ, GaspariAA. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol, 2012; 12:114–124.
55.
ShibataM, SuekiH, SuzukiH, et al.Impaired contact hypersensitivity reaction and reduced production of vascular endothelial growth factor in tumor necrosis factor-alpha gene-deficient mice. J Dermatol, 2005; 32:523–533.
KimN, NotikS, GottliebAB, et al.Patch test results in psoriasis patients on biologics. Dermatitis, 2014; 25:182–190.
58.
LearJ, EnglishJ. Severe and chronic allergic contact dermatitis responding to azathioprine therapy. J Dermatol Treat, 1996; 7(2): http://dx.doi.org/10.3109/09546639609089541.
59.
CassanoN, LoconsoleF, CovielloC, et al.Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol, 2006; 19:237–240.
60.
VergaraG, SilvestreJF, BetllochI, et al.Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol, 2002; 138:1258–1259.
61.
RosmarinD, BushM, ScheinmanPL. Patch testing a patient with allergic contact hand dermatitis who is taking infliximab. J Am Acad Dermatol, 2008; 59:145–147.
62.
ConnerE, BochnerBS, BrummetM, et al.The effect of etanercept on the human cutaneous allergic response. J Allergy Clin Immunol, 2008; 121:258–260.
63.
BurnessCB, McKeageK. Adalimumab: a review in chronic plaque psoriasis. Drugs, 2015; 75:2119–2130.
KaikoGE, HorvatJC, BeagleyKW, et al.Immunological decision-making: how does the immune system decide to mount a helper T-cell response?. Immunology, 2008; 123:326–338.
66.
CamposRA, SzczepanikM, ItakuraA, et al.Interleukin-4–dependent innate collaboration between iNKT cells and B-1 B cells controls adaptative contact sensitivity. Immunology, 2006; 117:536–547.
67.
NagaiH, UedaY, OchiT, et al.Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice. Br J Pharmacol, 2000; 129:299–306.
68.
TraidlC, JugertF, KriegT, et al.Inhibition of allergic contact dermatitis to DNCB but not to oxazolone in interleukin-4–deficient mice. J Invest Dermatol, 1999; 112:476–482.
69.
RoweA, BunkerCB. Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. Contact Dermatitis, 1998; 38:36–39.
70.
RackeMK, BonomoA, ScottDE, et al.Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med, 1994; 180:1961–1966.
71.
MuellerR, KrahlT, SarvetnickN. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med, 1996; 184:1093–1099.
72.
XuH, DiIulioNA, FairchildRL. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (IL) 4/IL-10–producing (TH2) negative regulatory CD4+ T cells. J Exp Med, 1996; 183:1001–1012.
73.
BiedermannT, MailhammerR, MaiA, et al.Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific TH2 cells. Eur J Immunol, 2001; 31:1582–1591.
74.
DieliF, AshersonGL, RomanoGC, et al.IL-4 is essential for the systemic transfer of delayed hypersensitivity by T cell lines. Role of gamma/delta cells. J Immunol, 1994; 152:2698–2704.
75.
SalernoA, DieliF, SireciG, et al.Interleukin-4 is a critical cytokine in contact sensitivity. Immunology, 1995; 84:404–409.
76.
AlbanesiC, ScarponiC, SebastianiS, et al.IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. J Immunol, 2000; 165:1395–1402.
77.
AshersonGL, DieliF, SireciG, et al.Role of IL-4 in delayed type hypersensitivity. Clin Exp Immunol, 1996; 103:1–4.
78.
DieliF, SireciG, ScireE, et al.Impaired contact hypersensitivity to trinitrochlorobenzene in interleukin-4-deficient mice. Immunology, 1999; 98:71–79.
79.
WeigmannB, SchwingJ, HuberH, et al.Diminished contact hypersensitivity response in IL-4 deficient mice at a late phase of the elicitation reaction. Scand J Immunol, 1997; 45:308–314.
80.
NeisMM, PetersB, DreuwA, et al.Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol, 2006; 118:930–937.
81.
HoltmeierW, KabelitzD. gammadelta T Cells link innate and adaptive immune responses. Chem Immunol Allergy, 2005; 86:151–183.
82.
PtakW, AskenasePW. Gamma delta T cells assist alpha beta T cells in adoptive transfer of contact sensitivity. J Immunol, 1992; 149:3503–3508.
83.
AskenasePW, PtakW, SzczepanikM. Gamma delta T cells in normal murine spleen assist immunized alpha beta T cells in the adoptive cell transfer of contact sensitivity: effect of Bordetella pertussis. Cyclophosphamide, and antisuppressor T cell monoclonal antibodies. Int Arch Allergy Immunol, 1995; 107:363.
84.
YokozekiH, WatanabeK, IgawaK, et al.Gammadelta T cells assist alphabeta T cells in the adoptive transfer of contact hypersensitivity to para-phenylenediamine. Clin Exp Immunol, 2001; 125:351–359.
HamiltonJD, Suárez-FariñasM, DhingraN, et al.Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol, 2014; 134:1293–1300.
87.
PuzaCJ, AtwaterAR. Positive patch test reaction in a patient taking dupilumab. Dermatitis, 2018; 29:89.
88.
JoshiSR, KhanDA. Effective use of dupilumab in managing systemic allergic contact dermatitis. Dermatitis, 2018; 29:282–284.
89.
MachlerBC, SungCT, DarwinE, et al.Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol, 2018. pii: S0190-9622(18)32345–4.
90.
GoldminzAM, ScheinmanPL. A case series of dupilumab-treated allergic contact dermatitis patients. Dermatol Ther, 2018; 24:e12701.
91.
Collantes-RodriguezC, Jimenez-GalloD, Ossorio-GarciaL, et al.Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab. Contact Dermatitis, 2018. Epub ahead of print.
92.
HootJW, DouglasJD, FaloLDJr. Patch testing in a patient on dupilumab. Dermatitis, 2018; 29:164.
93.
SureshR, MuraseJE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Rep, 2018; 4:899–904.
